Welcome to Imugene Investor Centre

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers.  Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our headquarters are located in Sydney, Australia. We also have research facilities and partnerships across the United States to advance our clinical programs.

You can reach our Investor Relations team by emailing shareholderenquiries@imugene.com. We also welcome inquiries through our website’s contact form. Please allow 48 hours for a response and please note, under the selective disclosure obligations of the ASX we are unable to respond to enquiries in a private email about matters which are not in the public domain.

Our Annual Reports, Half Yearly and Quarterly reports can be found here

Imugene is listed on the Australian Securities Exchange under the ticker code IMU.  Shares of Imugene can be purchased through online trading platforms that allow stock purchases of ASX listed stocks. You can also buy shares through any licensed brokerage firm.

Automic Group
Email: hello@automicgroup.com.au 
Phone: 1300 288 664 (within Australia) or +61 2 9698 5414 (international)
Address: Level 5, 126 Phillip Street, Sydney NSW 2000

Shareholders can check their shareholdings by logging into the Automic investor portal https://investor.automic.com.au

Imugene is currently conducting multiple clinical trials focused on both blood cancers and solid tumours. For detailed information, please visit our Clinical Trials page..

If you’re interested in participating in a clinical trial, please consult with your healthcare provider. You can find further information regarding eligibility and participating countries for our clinical trials at https://clinicaltrials.gov/

If eligible, your healthcare provider will need to contact the participating clinical trial site directly to refer you to the principal investigator.

As the sponsor of our clinical trials, Imugene, cannot be involved in the recruitment process.

Imugene is committed to upholding the highest ethical standards in our research and clinical trials. We adhere to all regulatory guidelines and work with independent review boards to ensure the safety and well-being of participants.

A complete list of our Board of Directors, along with their biographies and relevant experience, can be found here..

Our Corporate Governance Statement and policies can be found on our website here.

You can find our ASX announcements here and our company newsletters here. We also encourage you to follow us on our social media platforms (LinkedIn and X) for current updates.